

**IDENTIFICATION OF NOVEL APOPTOTIC MARKERS BASED ON  
HYBRIDOMA TECHNOLOGY**

**A THESIS SUBMITTED TO  
THE DEPARTMENT OF MOLECULAR BIOLOGY AND GENETICS  
AND THE INSTITUTE OF ENGINEERING AND SCIENCE OF  
BILKENT UNIVERSITY  
IN PARTIAL FULLFILMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF MASTER OF SCIENCE**

**By  
CEREN ÇIRACI**

**July, 2004**

I certify that I have read this thesis and in my opinion it is fully adequate, in scope and in quality, as a thesis for the degree of Master of Science.

---

Assist. Prof. Tamer Yağcı

I certify that I have read this thesis and in my opinion it is fully adequate, in scope and in quality, as a thesis for the degree of Master of Science.

---

Assist. Prof. Kamil Can Akçalı

I certify that I have read this thesis and in my opinion it is fully adequate, in scope and in quality, as a thesis for the degree of Master of Science.

---

Assoc. Prof. Ayhan Kubar

Approved for the Institute of Engineering and Science.

---

Prof. Dr. Mehmet Baray  
Director of Institute of Engineering and Science

## **ABSTRACT**

### **IDENTIFICATION OF NOVEL APOPTOTIC MARKERS BASED ON HYBRIDOMA TECHNOLOGY**

Ceren ıracı

M.S. in Molecular Biology and Genetics

Supervisor: Assis. Prof. Tamer Yağcı

July 2004, 64 Pages

Apoptosis is a physiological cell death program that is characterized by morphological changes such as nuclear condensation, membrane blebbing, cell shrinkage, DNA cleavage and formation of apoptotic bodies. It is required for normal development and maintenance of cellular homeostasis and dysregulation of apoptosis leads to several developmental abnormalities, progression of degenerative diseases and cancer development. Elucidating the mechanisms underlying this form of cell death and development of molecular markers for its identification are of great importance to understand tumorigenesis.

One way to generate molecular markers is based on monoclonal antibody-production. Utilization of such antibodies as apoptotic markers is strictly dependent on their molecular specificity and selectivity in terms of recognizing targeted proteins.

We produced monoclonal antibodies by using apoptotic Huh-7 hepatocellular carcinoma cells as immunogen, and chose two of them, namely 9C11 and 6D5 for further characterization in the context of apoptosis.

## ÖZET

### HİBRİDOMA TEKNOLOJİSİ KULLANILARAK YENİ APOPTOTİK BELİRTEÇLERİN TANIMLANMASI

Apoptoz hücre büzüşmesi, çekirdek yoğunlaşması, hücre zarı tomurcuklanması, DNA kırılması ve apoptoz cisimciklerinin oluşması ile tanımlanan fizyolojik bir hücre ölüm programıdır. Bu program normal gelişimin ve hücre sel homeostazinin sürekliliği için gerekli olup, bozukluğu koşullarında gelişimsel anomalilere, dejeneratif hastalıklara ve kanser gelişimine neden olmaktadır. Bu hücre ölüm biçiminin altında yatan mekanizmaları aydınlatmak ve tanımlanması için gerekli moleküler belirteçleri geliştirmek tümör oluşunu anlamak açısından çok büyük öneme sahiptir.

Moleküler belirteçleri geliştirmenin bir yolu monoklonal antikorların üretilmesidir. Bu tür antikorların apoptoz belirteci olarak kullanılması, hedeflenen proteinleri seçici ve özgül olarak tanımlanmalarına bağlıdır.

Apoptoz tetiklenmiş, hepatoselüler karsinom hücre dizisi, Huh7 hücrelerini immünojen olarak kullanıp monoklonal antikorlar geliştirdik ve bunlardan 9C11 ve 6D5 antikorlarını, apoptoz kapsamında daha ileri tanımlanmaları için seçtik.

## ACKNOWLEDGEMENT

It is my pleasure to express my deepest gratitude to my advisor Assist.Prof.Tamer Yağcı for his guidance, endless patience, laboratory discipline and efforts throughout my thesis work.

I would like to thank Prof. Mehmet Öztürk for his support and suggestions.

I wish to express my thanks to Hilal Çelikkaya for helping me with the experiments and for her friendship.

Thanks to Cemaliye Akyerli Boylu for helping me any time I needed especially when I was hungry.

Special Thanks to especially Elif Uz, Sevgi Bağışlar and Bâlâ Gür for mentally supporting me all the time and providing me a shoulder to cry any time I needed and laughing at even my worst jokes.

I should also thank to all friends in laboratory for their warm friendships and helps.

Thank you very much my dearest family for their invaluable supports, trust and being with me all the time.

## TABLE OF CONTENTS

	page
SIGNATURE PAGE	I
ABSTRACT	II
ÖZET	III
ACKNOWLEDGEMENTS	IV
TABLE OF CONTENTS	V
LIST OF TABLES	VIII
LIST OF FIGURES	IX
ABBREVIATIONS	XI
1. INTRODUCTION	
1.1. Apoptosis	1
1.2. Apoptotic pathways	2
1.3. Endogenous inhibitors of apoptosis	11
1.4. Oxidative stress	12
1.5. Apoptosis detection methods	12
1.6. Hybridoma technology and monoclonal antibodies	14
1.7. Aim and strategy	15
2. MATERIALS AND METHODS	
2.1. Production and screening of hybridomas	16
2.2 Culture and maintenance of hybridomas.	17
2.3.Purification of the antibodies	18
2.4.Subculturing of HUH-7 Cells	19
2.5.Immunoflouresence with 6D5 and 9C11	19

2.6.Immunoperoxidase	20
2.7.Protein extraction from cells (preparing cell lysates)	21
2.8.Western Blotting	22
2.9.Immunoprecipitation (IP) with 9C11 and 6D5	28
2.10.Induction of apoptosis by UV-C	28
2.11.Induction of apoptosis by activation of death-receptor mediated apoptosis	29
2.12.Induction of apoptosis by serum starvation	29
2.13.Induction of apoptosis by oxidative stress	29
2.14.Kinetic assays	30

### 3. RESULTS

3.1. Production of monoclonal antibodies.	31
3.2. Comparison assay for 11G8, 6D5, 6E10 and 9C11	32
3.3.Biochemical characterization	33
3.4. Kinetic Assays in different apoptosis induction methods	36
3.4.1. UV induction	36
3.4.2. Starvation	38
3.4.3. H <sub>2</sub> O <sub>2</sub> treatment	41
3.4.4. Starvation and H <sub>2</sub> O <sub>2</sub> treatment	42
3.5 Immunofluorescence and Immunoperoxidase with 9C11 and 6D5	44
3.5.1. Kinetic assay in UV-induced apoptosis	44
3.5.2. Kinetic assay in starvation	46
3.5.3. Kinetic assay in oxidative stress.	50
3.5.4. Kinetic assay in starvation and oxidative stress.	52

4. DISCUSSION	54
---------------	----

Page





## LIST OF TABLES

	page
Table 1      Comparison of apoptotic and necrotic cells	2

## LIST OF FIGURES

	page
Figure 1. Death receptor structure	6
Figure 2. Intrinsic pathway	9
Figure 3. Caspase proenzyme organization	10
Figure 4. Two principal pathways of apoptosis signal transduction	12
Figure 5. Antibody presence in the supernatants of four hybridomas	32
Figure 6. Immunoprecipitated HUH7 cell lysates	32
Figure 7. Western Blotting with 9C11 and 6D5 monoclonal antibodies	33
Figure 8. Different protein concentrations with 9C11.	34
Figure 9. Different protein concentrations with 6D5.	35
Figure 10. Kinetic assay in UV-induced apoptosis.	36
Figure 11. Kinetic assay in UV-induced apoptosis.	37
Figure 12. Annexin V Assay	38
Figure 13. Kinetic assay in Starvation with 9C11	39
Figure 14. Kinetic assay in Starvation with 6D5	40
Figure 15. Kinetic assay in oxidative stress with 9C11	41
Figure 16. Kinetic assay in oxidative stress with 6D5	42
Figure 17. Kinetic assay in starvation and oxidative stress with 9C11	43
Figure 18. Kinetic assay in starvation and oxidative stress with 6D5	43
Figure 19. Immunofluorescence with 9C11 in UV induction.	45
Figure 20. Immunofluorescence with 6D5 in UV induction.	46
Figure 21. Immunofluorescence with 9C11 in starvation.	48
Figure 22. Immunofluorescence with 6D5 in starvation.	49
Figure 23. Immunoperoxidase assay in oxidative stress with 9C11.	50
Figure 24. Immunoperoxidase assay in oxidative stress with 6D5	51
Figure 25. Immunoperoxidase assay with 9C11 in starvation and oxidative stress	52

Figure 26. Immunoperoxidase assay in starvation and  
oxidative stress with 6D5

## ABBREVIATIONS

APS	Ammonium persulfate
Bisacrylamide	N, N, methylene bis-acrylamide
BSA	Bovine serum albumin
ddH <sub>2</sub> O	double distilled water
EtOH	ethanol
EDTA	Ethylenediaminetetra-acetic acid
FITC	Fluorescein isothiocyanate
FCS	Fetal calf serum
g	gram
H <sub>2</sub> O <sub>2</sub>	hydrogen peroxide
HRP	horseradish peroxidase
KDa	kilodalton
Lt	liter
ng	nanogram
M	molar
min	minute
ml	milliliter
mM	millimolar
μl	microliter
μg	microgram
NaCl	sodium chloride
NaOH	sodium hydroxide
rpm	revolution per minute
SDS	sodium dodecyl sulphate
PAGE	Polyacrylamide gel electrophoresis
TEMED	N, N, N, N-tetramethyl-1-2, diaminoethane
UV	ultraviolet
v	volt
DMEM	Dulbecco's Modified Eagle's Medium

PEG	Polyethilen Glycol
AP	Alkaline Phoshatase
O/N	overnight
TBS-T	Tris Buffer Saline-Tween-20

## 1. INTRODUCTION

### 1.1 Apoptosis

Apoptosis is a physiological cell death program that was first described in modern scientific world by the article of Kerr, Wyllie and Currie (1972). Apparently, apoptosis was chosen for its meaning of falling of leaves in ancient Greek (Kerr et al, 1972).

Apoptosis is a programmed cell death process that is necessary for eliminating cells which are no longer needed and a fundamental biological process required for normal development and homeostasis in multicellular organisms (Wyllie, 1980). Dysregulation of apoptosis causes some developmental abnormalities and diseases. Morphologically, apoptosis is defined by cell shrinkage, membrane blebbing, DNA cleavage and the formation of apoptotic bodies (Miller *et al.*, 2001). Apoptosis is distinguished from necrosis by these features. Transition from normal to shrunken form and blebbing are rapid, typically take 10-30 minutes, and at that point apoptotic cells are phagocytosed either by their nearest neighbors or by professional macrophages (Zörnig *et al.*, 2001).

In contrast, necrotic cells initially increase their cellular water content and by this way they also increase their volume. The nuclei lose the typical chromatin structure, which is seen as irregular clumping or dissolution and cell membrane ruptures, secretes the cellular contents into the environment. There are some criteria for distinguishing apoptosis from necrosis.

**Table 1: Comparison of apoptotic and necrotic cells** (Richter, 1993; Studzinski, 1999).

	<i>Apoptosis</i>	<i>Necrosis</i>
<b>Nuclei</b>	Dense condensation of chromatin	Karyolysis is preceded by irregular chromatin clumping
<b>Cytoplasmic organelles</b>	Morphologically intact	Disrupted
<b>Cell membrane</b>	Apoptotic bodies, blebbing	Blebbing and loss of integrity
<b>Cell volume</b>	Cells shrinks	Cells swell
<b>In tissues</b>	Single cell affected	Groups of cells affected
<b>Tissue response</b>	None	Inflammation

## 1.2 Apoptotic pathways

Apoptosis takes place in two ways:

- i) The death receptor (DR) or extrinsic pathway
- ii) The mitochondrial or intrinsic pathway.

External signals or internal signals come and activate a initiator proteases, which subsequently activate the amplifier caspases, causing the activation of effective proteases. Sequential activation of successive proteases (caspases) provides a fail-safe mechanism that makes possible to abort a premature apoptotic signal and it also serves to amplify the signal to lead rapid finalization of an irrevocable decision to self destruct ( Studzinski, 1999).

*Death receptor pathway* involves oligomerization of cell surface receptors to trigger the apoptotic pathway. Liver cells generally express DRs perhaps due to evolutionary pressure to omit hepatotropic viruses.

*Mitochondrial pathway* is mediated by DNA damage, changes of intracellular  $\text{Ca}^{+2}$ , and endoplasmic stress response (Yoon *et al.*, 2002). Many types of cellular stress, including starvation, oxidative damage cause initiation of intrinsic pathway where caspase activation follows signals transduced at the level of the mitochondria. (Özören *et al.*, 2002).


Activated molecular pathways differ according to DNA damage type, meaning that the nature of DNA structure recognized by the sensors defines the steps to follow. Depending on their functions within the signaling cascade, there are three types of proteins called sensors, transducers and effectors. Sensors are involved in DNA damage response and detect the damage, transducers transmit the signal where damage is present and effectors elicit the various specific biological responses (Stergiou *et al.*, 2004).

### **Extrinsic pathway (apoptosis via death receptor)**

DRs are cell surface receptors belonging to the tumor necrosis factor (TNF) receptor superfamily and trigger apoptosis after binding to their ligands or in experimental conditions, agonistic antibodies (Ashkenazi, 2002). TNF was isolated more than 15 years ago and reported to have the ability to kill tumor cells in vitro (Schulze-Osthoff *et al.*, 1998). TNF is a pleiotropic cytokine that is predominantly produced by macrophages and T cells. It induces proliferation, displays cytolytic activity against tumor cells and also induces inflammatory responses and regulates immun responses. TNF mediates its biological effect through TNFR-I and TNFR-II (Gupta, 2001). DRs share a significant homology. They all have an extracellular



ligand-binding domain, and 60-80 amino acid cytoplasmic sequence known as the death domain. They differ in their cytoplasmic domains. TNFR-I contains DD (Death Domain), whilst TNFR-II does not. TNFRs do not display enzymatic activity, and thus they have to depend on recruitment of other adapter molecules for signaling (Gupta, 2001).



**Figure 1: Death receptor structure** (Yoon *et al.*, 2002).


There are six known DRs that are reported. Fas (CD95), Tumor necrosis factor receptor 1(TNF-R1), Tumor necrosis factor related apoptosis inducing ligand (TRAIL) receptor 1 (DR4), TRAIL2 (DR5), DR3 (APO3) and DR6. Among these six death receptors, apoptosis signaling pathways mediated by Fas, TNF-R1 and TRAIL receptors have roles in the apoptosis that occurs in the liver. Pro-apoptotic signaling

is similar in all known death receptors. As mentioned above, after the binding of the ligand or specific agonistic antibody, DRs are oligomerized which leads to the recruitment of the cytoplasmic adapter protein. There are two major classes of adaptor molecules: 1) TRAFs and 2) FADD molecules. They both contain a death effector domain (DED) causing the recruitment of caspases via the association with a corresponding death effector domain in the prodomain of the inactive initiator caspases, caspase 8 and 10. The selective recruitment of adapter molecules is determined according to whether they contain a DD or TRAF binding motif (Kasibhatla *et al.*, 2003).

The final complex is called death-inducing signaling complex (DISC). TNF-R1 and TRAIL R1-R2 receptors are activated as defined above. Death receptor mediated apoptosis can be regulated at the level of DISC formation.(Yoon *et al.*, 2002)

### **Intrinsic pathway (apoptosis via mitochondria)**


Mitochondria are composed of two well-defined compartments: the matrix, surrounded by the inner membrane and the intermembrane space, surrounded by the outer membrane. The inner membrane contains various molecules such as ATP synthase, electron transport chain proteins etc. Under normal conditions, these molecules provide an electrochemical gradients (membrane potential). The outer membrane contains a voltage- dependent anion channel. The intermembrane space contains cytochrome-c, procaspases, apoptosis-inducing factor (AIF). Permeabilization of the outer membrane during apoptosis results in the releases of cytochrome-c (Figure 2) (Gupta, 2001).



**Figure 2: Intrinsic pathway** (Goel and Khanduja, 1998) AIF: apoptosis inducing factor; Cyt C: cytochrome C;  $\text{Ca}^{++}$ : calcium; ROS: reactive oxygen species; PS: phosphatidylserin; PC: phosphatidylcholine).

The primary event is the initiation of cytochrome c release from the intermembrane space of mitochondria into the cytoplasm where it makes a complex with Apaf 1 and procaspase 9, called “apoptosome”. Initiator procaspase 9 becomes active and then activates other downstream effector caspases (Özören *et al.*, 2002).

Caspases have primary roles in apoptotic pathways. In this respect, caspases certainly constitute the key effector molecules that are required for in most apoptotic pathways. They are cysteine proteases, which cleave their substrates after an Asp residue. All caspases are synthesized as zymogens that need to be proteolytically cleaved. Active enzyme is composed of a heterotetrameric complex of two large subunits of approximately 20 kDa containing the active center and two small subunits of 10 kDa (Figure 3) (Schulze-Osthoff *et al.*, 1998).



**Figure 3: Caspase proenzyme organization** (Nicholson, 1999).

There are 11 caspases in the human genome. Eight of the human caspases (caspases 2, 3, 6, 7, 8, 9, 10, and 14) function in apoptosis. Two processes lead to the conversion of a latent apoptotic caspase to the enzymatically active form: 1) binding to a caspase activator protein (e.g. Apaf-1) and 2) proteolytic cleavage by another active caspase. Caspases function in cells in a hierarchical order involving “upstream” activator caspases (e.g. caspases 8, and 9) that cleave and activate “downstream” effector caspases (e.g. caspases 3 and 7). In addition, the caspases are divided between two different apoptosis pathways: 1) the death receptor or “extrinsic” pathway in which caspase 8 is the upstream activator caspase; and 2) the mitochondrial or “intrinsic” pathway in which caspase 9 is the upstream activator


caspase. The death receptor and mitochondrial pathways converge at the level of the downstream effector caspases. It has been reported that both pathways are capable of operating in most cell types (Degterev *et al.*, 2003).

### **Subgroups of Caspases**

ICE-subfamily	Caspase-1, 4,5,11,12,13,14
Ced3/CPP32 subfamily	Caspase-3,6,7
ICH-1/Nedd2 subfamily	Caspase –2,8,9,10

One of the primary regulators of intrinsic way of apoptosis is the family of Bcl-2 proteins. Bcl-2 family proteins play critical roles in the regulation of programmed cell death. Changes in the level or bioactivities of these proteins are associated with a variety of physiological processes where cell death occurs, including fetal development, normal cell turn over in epidermis and immune cell differentiations etc (Reed, 1998;Adam and Corry, 1998). These proteins are classified into proapoptotic members that include Bax, Bak, Bik, Bad, Bid and anti-apoptotic proteins such as Bcl-2 and Bcl-x<sub>L</sub> based on their ability to suppress or induce the release of cytochrome c.

Although they have opposing activities, all members of the Bcl-2 family proteins contain at least one of the four so-called BH domain (BH1-BH4). Proapoptotic members contains BH3 domain. For example, Bid is a proapoptotic protein that functions to facilitate the activity of other members of the proapoptotic family such as Bax and Bak. The BH3 domain of Bid mediates interaction between various members of the Bcl-2 family to generate a number of heterodimers and homodimers (Kasibhatla *et al.*, 2003).



**Figure 4: Two principal pathways of apoptosis signal transduction (Schulze-Osthoff *et al.*, 1998)**

There is a considerable cross talk between extrinsic and intrinsic pathways. For example, caspase 8 can proteolytically activate Bid, which can then lead to release of cytochrome c (Green, 2000). This apparently increases the apoptotic signal following death receptor activation (Fulda *et al.*, 2001).

### 1.3 Endogenous inhibitors of apoptosis

As mentioned above Bcl-2 family members have proapoptotic and anti-apoptotic roles during apoptosis. It has been reported that Bcl-2 and Bcl-x<sub>L</sub> inhibit cytochrome-c release. In addition to anti-apoptotic Bcl-2 family members, there are some other inhibitors of apoptosis (Gupta, 2001). The inhibitors of apoptosis protein family (IAP) consist of Neural Inhibitor of Apoptosis Protein (NIAP), X-linked

Inhibitor of Apoptosis Protein (X-IAP), survivin, c-IAP1, c-IAP2 (Deveraux and Reed, 1999). IAPs contain 70 amino-acid motifs termed the BIR (Baculovirus IAP Repeats) domain. IAPs inhibit apoptosis by inhibiting caspase activity through the interaction with caspase 3, 7, 9 but not caspase 1, 6, 8 or 10. XIAP contains the second BIR domain (BIR2), which inhibits caspase 3 and 7 (Gupta 2001). Recently heat shock protein 70 has been reported to have an inhibitory effect on apoptosis (Jaattela *et al.*, 1998). Survivin is another apoptosis inhibitory protein that has structural similarity to IAPs and the only apoptosis inhibitor protein expressed selectively in most human cancers but lacking from normal adult tissue.

#### **1.4 Oxidative stress**

Recent studies indicate that apoptosis can be induced by exogenous oxidants (Hockenbery *et al.*, 1993). Several lines of evidence support a role for oxidative stress as a mediator of apoptosis. Both ionizing radiation, which generates reactive oxygen species (ROS) and H<sub>2</sub>O<sub>2</sub> treatment can cause apoptosis.

H<sub>2</sub>O<sub>2</sub> causes dose and time dependent reduction of survival of hepatoma cells and also resulted in an increase in the number of detaching cells from the surface of the culture dish. Loss of adhesion is the feature of apoptotic cells and results in a morphological changes. H<sub>2</sub>O<sub>2</sub> may destroy Ca<sup>2+</sup> homeostasis, damage membrane receptors and activate signal transduction system and lead to the apoptosis. Exposure to H<sub>2</sub>O<sub>2</sub> causes a decrease in levels of Bcl-2 protein in some hepatoma cells (Li *et al.*, 2000).

#### **1.5 Apoptosis detection methods**

Apoptosis is distinguished morphologically from necrotic, non-apoptotic cells by some features as mentioned above. Detection of apoptosis in cells and tissues is

an important issue both to study the molecular mechanism of apoptosis and roles of apoptosis in diseases. To detect apoptosis, apoptotic features such as activation of death receptors, formation of cytochrome c/Apaf-1 complex, caspase activation, phosphatidylserine exposure, DNA laddering, morphological changes are considered

### **Analysis of morphological changes of apoptosis**

Since the discovery of apoptosis, the morphological changes associated with apoptosis have been widely used to detect apoptotic cell death. These morphological changes include, membrane blebbing, shrinking of cytoplasm, condensation of nucleus and formation of apoptotic bodies.

Although useful in later stages of apoptosis, it is not possible to detect apoptosis in early stages and measure the total amount of the apoptotic cells.

### **DNA fragmentation assays**

DNA laddering takes place during apoptosis, because of the presence of caspase dependent endonucleases. Agarose gel electrophoresis is a commonly used method to detect the ladder pattern of DNA, but it is not possible to quantify the result.

### **TUNEL Assay (TdT-mediated conjugated dUTP nick end-labeling)**

During apoptosis, after cleavage of DNA, single strand breaks in high molecular weight and double stranded DNA in low molecular weight are formed. These fragments can be detected by TUNEL assay. This can be achieved by enzymatic labeling of 3'-OH ends of fragmented DNA. For incorporation of labeled nucleotides into DNA strand breaks, terminal deoxynucleotidyl transferase (TdT) can



be used. This method is known as TUNEL assay (Gavrieli *et al.*, 1992). The disadvantage of this method is that late necrotic cells, showing DNA degradation, is also labeled.

### **Annexin V**

Annexin V is a method, which is generally used to detect apoptosis. Annexin V belongs to calcium- dependent phospholipid-binding protein family; therefore it binds phosphatidylserine (PS) in the presence of calcium ions. PS in cell membrane is externalized to the surface in very early stages of apoptosis by the action of flippases. Annexin V is used to detect PS in the outer membrane that has occurred after any kind of cell membrane injury.

### **1.6 Hybridoma technology and monoclonal antibodies**

Monoclonal antibodies (mAb) are essential reagents that are used in several fields such as diagnosis of diseases, treatment of diseases such as infections and cancer. The first and now generally used method for producing homogeneous or monoclonal antibodies of known specificity was described by George Köhler and Cesar Milstein in 1975. This technique is based on the fact that each B lymphocyte produces antibody of a single specificity. Since normal B-lymphocytes cannot grow indefinitely, it is necessary to immortalize B cells that produce a specific antibody. This is achieved by cell fusion between a normal antibody producing B cell and a myeloma cell, followed by selection of fused cells that secrete antibody of the desired specificity derived from the normal B cell. Such fusion-derived immortalized antibody-producing cell lines are called hybridomas, and the antibodies they produce are monoclonal antibodies (Abbas and Lichtman, 2003). Cell lines or clones taken from animals that have been immunized with the substance that is the subject of study produce these antibodies (Nelson *et al.*, 2000).

The therapeutic potential of monoclonal antibodies (mAb) was realized after the hybridoma technique gave rise their development in the mid 1970s as mentioned

above. Since then many therapeutic strategies have been developed particularly in the treatment of cancer. (Breedveld, 2000). “Rituximab” was the first produced antibody that is directed against CD20. It is a transmembrane protein on pre- and mature B-lymphocytes. Growth factors are also used as targets for the generation of monoclonal antibodies. For example, antibodies directed to epidermal-growth-factor receptors inhibited the growth of some tumors. Trastuzumab (Herceptin), which is a humanized IgG1 mAb, have been used successfully in the treatment of breast cancer (Breedveld, 2000).

### **1.7 Aim and Strategy**

This project aims to produce mAbs against proteins that are differentially expressed in apoptotic cells and to investigate these Abs as novel apoptotic markers. In our study, UV induced apoptotic HUH-7 cells were injected into mice to obtain mAbs. Cell ELISA assays were performed in order to screen hybridoma clones reacting with apoptosis induced HUH-7 cells. The next step was to explore the differential expressions of antigens recognized by these monoclonal antibodies in apoptotic and non-apoptotic cells. For this purpose, immunofluorescence, immunoprecipitation, and western blotting assays were performed.

## **2.MATERIALS AND METHODS**

### **2.1. Production and screening of hybridomas**

9C11, 6D5 and other monoclonal antibodies were previously produced by Tamer Yağcı. One to five millions of apoptotic Huh-7 cells were injected four times into the peritoneal cavity of Balb/c mice at 3 weeks intervals. After the last injection splenic cells of immunized mice were fused with SP2/0 mouse myeloma cells by using polyethylene glycol (PEG), and antibody producing hybridomas were screened by cell-ELISA. Positive clones were further subcloned to ensure the monoclonality and 6D5 and 9C11 antibodies were chosen for further characterization studies.

#### **Cell ELISA (Enzyme-Linked Immunosorbent Assay)**

The Cell-ELISA assay was performed to screen the hybridomas in order to identify positive clones, which secrete antibodies recognizing apoptotic Huh-7 cells. To do this Huh-7 cells were cultured in 96 well plates in Dulbecco's Modified Eagle's Medium (DMEM) containing % 10 FCS, 1% penicillin/streptomycin and 1% non-essential amino acid (DMEM-10 thereafter). Plates were incubated overnight in CO<sub>2</sub> incubator at 37° C and the next day wells were washed two times with PBS.

Cells were fixed with 125 µl. of 4% formalin / well (formalin was prepared freshly in PBS) for 15 minutes. After one wash with PBS, cell permeabilization was performed by using 125 µl. of 0.2% Triton X-100 / well for 5 minutes (Triton X-100 was prepared in PBS), and then wells were washed twice with ddH<sub>2</sub>O.

*For Blocking*, 250 µl. of 2% BSA in PBS was added to the wells and incubated at 37°C for 1 hour. After discarding the blocking solution, previously collected supernatants were added to the wells (50 µl.), incubated 2 hours at 37°C (Primary

Antibody) and washed with twice ddH<sub>2</sub>O. DMEM-10 medium was used as a negative control.

Alkaline phosphatase (AP) conjugated secondary antibody was prepared in 1% BSA-PBS from a stock solution (Rabbit anti-mouse AP Sigma) in 1:1000 dilution, added to each well and incubated at 37°C for 1 hour. Meanwhile, substrate and buffer tablets (Sigma Fast p-Nitrophenylphosphate Tablet sets p(NPP) Alkaline Phosphatase Substrate) were dissolved in ddH<sub>2</sub>O and kept in the dark. Wells were washed 4 times with distilled water and previously prepared substrate mixture was added to the wells and left 45-60 minutes at room temperature. When color change was observed in the wells, plates were read at A<sub>405</sub> in ELISA reader (Beckman Biomek 2000).

## **2.2 Culture and maintenance of hybridomas.**

The frozen 9C11 and 6D5 antibody producing hybridoma stocks were cultured in high glucose DMEM supplemented with 10% fetal calf serum. FCS, 1% penicillin/streptomycin, 1% nonessential aminoacids and %1 L glutamine. Cells were grown at 37°C and 5% CO<sub>2</sub> and hybridoma supernatants were collected by centrifugation of the culture medium at 1500 rpm for 5 minutes at 4°C. This collected supernatants were buffered with 1 M of Tris-HCl pH. 8 to reach a final concentration of 20 mM Tris-HCl; Na Azide was added at a final concentration of 0.02%. Stocks of hybridomas were frozen in freezing medium containing 90% FCS and 10% dimethylsulfoxide (DMSO) and kept in liquid nitrogen tank.

To thaw frozen cells, one vial of hybridomas was taken from nitrogen tank and transferred into the ice immediately. Then, vial was placed into 37°C water bath until complete dissolution. Cells then were transferred into the centrifuge tubes and washed once with complete DMEM. After centrifugation at 1500 rpm at 4°C for 5 minutes, supernatant was discarded and the resuspended pellet was poured in 10 ml of warm culture medium into 25 cm<sup>2</sup> flasks. The viability of cells was checked in the following days.

Growing hybridomas were split twice a week in 1:4 to 1:5 ratio. Each time supernatants were collected by centrifuging the culture medium at 1500 rpm for 5 minutes and stored at 4° C.

#### **PBS solution (10X)**

NaCl	80 g
KCl	2 g
Na <sub>2</sub> HPO <sub>4</sub> 2H <sub>2</sub> O	7.64 g
KH <sub>2</sub> PO <sub>4</sub>	2 g

Complete to 1L with distilled water (pH:7.4).

### **2.3.Purification of the antibodies**

Protein G coated agarose beads were washed three times with PBS, each for 15 minutes. 6D5 and 9C11 supernatants, each 100 ml, were completed to 200 ml. with PBS and incubated with washed beads at room temperature for 2 hours by rotating continuously. Supernatants were centrifuged at 2500 rpm for 2 minutes and the protein G pellets were washed three times with PBS. Antibodies were eluted in elution buffer at pH 2.6. And neutralized immediately with Tris-HCl pH 8.8.

Protein concentration was determined by measuring the OD values of eluates at A<sub>280</sub>. Eluates were also run in Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis (SDS-PAGE) and protein bands visualization was accomplished by coomassie staining. Antibody purification experiment was also performed with ascite fluids generated in nude mice. 9C11 and 6D5 eluates were dialyzed against PBS.

## **Elution buffer**

0,1 M glycinehydrochloride, pH 2.6

For 1 lt: To 900 ml deionized water, add 7.51 g of glycine. Adjust pH to 2.6 with 5N hydrochloric acid. (HCl). Add deionized water to a final volume of 1000 ml.

## **2.4.Subculturing of HUH-7 Cells**

Cells were splitted once a week and renewal of culture medium was done every 3 days. For splitting, medium was aspirated and the cells were washed twice with PBS. Trypsin (BIOCHROM AG) was added to the plates and plates were incubated in the incubator for 3-5 minutes until the cells are detached. Detached cells were transferred to the centrifuge tubes, centrifuged at 1500 rpm for 5 minutes. Cell pellets were resuspended in fresh DMEM-10 and plated in the desired dilution into new plates.

## **2.5.Immunoflourescence with 6D5 and 9C11**

Huh-7 cells were grown on sterile cover slips in 6 well plates and incubated overnight to allow cells attach the cover slips. Cells were washed twice with PBS and fixed with ice-cold methanol for 10 minutes at  $-20^{\circ}\text{C}$ . Since methanol was used, permeabilization step was skipped and after two wash steps with PBS, cells were incubated with 9C11 and 6D5 supernatants at room temperature for 1 hour. After washing three times with PBS, Fluoresceinisothiocyanate FITC-conjugated goat-anti-mouse antibody (DAKO) was used as the secondary antibody and diluted at a ratio of 1:200 in 20 mM Tris HCl pH 8. An incubation of 1 hour at room temperature in the dark was followed with 4 PBS washes. In each immunoflourescence experiment, cells were counterstained with Hoechst 33258 (Sigma). Cells were incubated for 10 minutes in the dark, with the dye at a dilution of 1:700. Cover slips were washed with distilled water for 10 minutes and each cover slip was placed on a microscope slide

by using mounting solution. Slides were examined under fluorescent microscope (Zeiss).

#### **Hoechst solution**

Hoechst 33258 dye stock solution: 400 µg/ml in water

Hoechst 33258 dye final solution: 3 µg/ml

#### **Mounting Solution:**

50% glycerol

50% ddH<sub>2</sub>O

### **2.6.Immunoperoxidase**

Huh-7 cells were grown on sterile cover slips in 6 well plates and incubated overnight to allow cells attach the cover slips. The next day, medium was aspirated and the cells were washed three times with PBS and fixed with ice-cold methanol for 5 minutes at -20° C. After fixation methanol was aspirated, wells are washed with PBS and left at room temperature for the evaporation of remaining methanol. To prevent nonspecific binding, cover slips were blocked with PBS containing 10% FCS and the blocking step lasted 30 minutes at room temperature. At the end of this incubation, blocking solution was aspirated and wells were rinsed once with PBS. Then, fixed cells were incubated with primary antibody for 1 hour at room temperature. Wells were washed three times with PBS and each cover slip was covered with 2 drops of Biotinylated secondary Ab for ten minutes. After another washing with PBS, cover slips were treated with 2 drops of strepto avidin-horse radish peroxidase for ten minutes and washed again with PBS. Then, DAP was prepared very quickly as recommended by the manufacturer, added to the each well, and color development was observed (1 to 5 min.). Reaction was stopped by rinsing the cover slips with distilled water and hematoxyline counterstaining was performed for the visualization of nuclei. To get rid of hematoxyline background, cover slips were washed thoroughly with distilled water. Finally, each cover slip was mounted onto glass slides by using mounting solution.

## **2.7. Protein extraction from cells (preparing cell lysates)**

When cells grown to 70-80% confluency, they were washed twice with ice cold PBS, scraped in a small volume of the same buffer and centrifuged at 1500 rpm for 5 minutes at 4°C. Pellets were either kept at –80°C or lysed immediately in NP-40 lyses buffer.

**NP-40 lyses buffer:** 150 mM NaCl  
1% NP-40 (Igepal-Sigma)  
50mM Tris (pH 8.0)

For lysis, the pellets were resuspended in 4 to 5 volume of NP-40 lyses buffer supplemented with protease inhibitors (Roche; EDTA free complete protease inhibitor cocktail) and incubated on ice for 30 minutes. The lysates were centrifuged at 13000 rpm for 30 minutes at 4°C. Supernatants were transferred into fresh tubes and following protein quantitation; proteins were aliquoted and stored at –80°C.

### **Bradford Stock solution**

Ethanol (95%)	4,75 ml
dH <sub>2</sub> O	250 µl
Phosphoric acid (85%)	10 ml
Coomassie Brilliant Blue	17,5 mg

### **Bradford Working solution**

dH <sub>2</sub> O	21.25 ml
Ethanol (95%)	0,75 ml
Phosphoric acid (85%)	1,5 ml
Bradford stock solution	1,5 ml



## Bradford Assay for Protein Quantitation

A standard curve was prepared by using BSA as described below:

<b>Tubes</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>	<b>6</b>	<b>7</b>	<b>8</b>
<b>BSA(μl)</b>	0	2.5	5	7.5	10	12.5	15	20
<b>dH<sub>2</sub>O(μl)</b>	100	97.5	95	92.5	90	87.5	85	80
<b>Bradford working solution(μl)</b>	900	900	900	900	900	900	900	900

Protein samples were prepared as described below:

<b>Tubes</b>	<b>1</b>	<b>2</b>	<b>3</b>	<b>4</b>	<b>5</b>
<b>Samples</b>	0	2	2	2	2
<b>dH<sub>2</sub>O (μl)</b>	98	98	98	98	98
<b>Bradford (μl)</b>	900	900	900	900	900
<b>Lysis buffer (μl)</b>	2	-	-	-	-

A<sub>595</sub> values were measured immediately (5-30 min.).

## 2.8. Western Blotting

### SDS-Polyacrylamide gel electrophoresis of proteins

#### *For resolving gel*

The glass plates were casted according to the user guide instructions. SDS-PAGE gels with different acrylamide concentrations were prepared considering the linear range of separation (kD). Acrylamide solution was prepared quickly, poured into the space between the glass plates and overlaid with a thin layer of iso-butanol. After polymerization was complete, iso-butanol was removed and the surface of the gel was washed several times with deionized water. Any remaining water was discarded by using the edge of a paper towel.

### *For stacking gel*

This was prepared in a disposable plastic tube at an appropriate volume and desired concentration. Then, the stacking gel solution was poured onto the surface of the resolving gel. The comb was immediately inserted into the stacking gel avoiding air bubble formation. The gel was placed in a vertical position at room temperature.

While the gel was polymerizing, samples to be loaded were prepared by boiling them in 1X SDS gel-loading buffer at 100° C for 5 minutes to denature the proteins. After the polymerization of the stacking gel was complete, the comb was removed carefully and each well was checked to discard any unpolymerized acrylamide. The gel was placed in the electrophoresis apparatus and electrophoresis running buffer was poured into top and bottom reservoirs. Any bubble were removed carefully by using a syringe and 5-100 µg of protein was loaded into the wells.

The electrophoresis apparatus was attached to the power supply and the gel was run at a constant volt (80) until the dye has passed to the resolving gel. Then, as the dye reached the resolving gel, voltage was increased to 120-150 volt. When the dye reached the bottom of the gel, power supply was turned off and the glass plates were removed from the apparatus. Plates were separated by using a spatula and the gel was transferred into transfer buffer.

## **Reagents for SDS –PAGE gel preparation**

### **Stock solutions**

#### **Acrylamide/bisacrylamide**

Acrylamide	(29.2 g /100 ml)	146 g
------------	------------------	-------

N’N’-Bis-methylene-acrylamide	(0,8 g/100 ml)	4 g
-------------------------------	----------------	-----

Made to 500 ml with distilled water. Filtered and stored at 4° C in the dark (30 days max)

**1.5 M Tris-HCl pH:8.8**

Tris-Base (18.15 g/100 ml)                      54.45 g

Distilled water                                      150 ml

Adjusted to pH:8.8 with 1N HCl; made to 300 ml with distilled water and stored at 4°C.

**0.5M Tris-HCl pH:6.8**

Tris-Base                      6 g

Distilled water    60 ml

Adjusted to pH: 6.8 with 1N HCl. Made to 100 ml with distilled water and stored at 4° C.

**10% SDS**

10 g SDS was dissolved in water with gentle stirring and completed to 100 ml with distilled water.

**Sample Buffer (SDS reducing buffer )-5X**

( Stored at room temperature)

0.225M    Tris    pH:6.8

50%            Glycerol

5%              SDS

0.05%        BPB(Bromophenol Blue) -add freshly

0.25M        DTT (reducing)

Completed to 40 ml.

### **Electrophoresis buffer (Running Buffer) -5X**

Tris- Base      45 g

Glycine        216 g

SDS            15 g

Completed to 3 lt with distilled water.

Store at 4°C.

Diluted to 1X before using; pH adjustment with acid or base not required.

### **Components for preparing 10% resolving gel**

<b>10% Gel</b>	<b>5 ml</b>	<b>10 ml</b>	<b>15 ml</b>	<b>20 ml</b>	<b>25 ml</b>
<b>dH<sub>2</sub>O</b>	1.9	4	5.9	7.9	9.9
<b>30% mix</b>	1.7	3.3	5	6.7	8.3
<b>1.5 M Tris (pH 8.8)</b>	1.3	2.5	3.8	5	6.3
<b>10% SDS</b>	0.05	0.1	0.15	0.2	0.25
<b>10% APS</b>	0.05	0.1	0.15	0.2	0.25
<b>TEMED</b>	0.002	0.004	0.006	0.008	0.01

### **Components for preparing 5% stacking gel**

<b>5% Gel</b>	<b>1 ml</b>	<b>2 ml</b>	<b>3 ml</b>	<b>4 ml</b>	<b>5 ml</b>
<b>dH<sub>2</sub>O</b>	0.68	1.4	2.1	2.7	3.4
<b>30% mix</b>	0.17	0.33	0.5	0.67	0.83
<b>1.5 M Tris (pH 6.8)</b>	0.13	0.25	0.38	0.5	0.63
<b>10% SDS</b>	0.01	0.02	0.03	0.04	0.05
<b>10% APS</b>	0.01	0.02	0.03	0.04	0.05
<b>TEMED</b>	0.001	0.002	0.003	0.004	0.005

## **Transfer of proteins from SDS-polyacrylamide gels to solid supports**

After the running process was complete, four pieces of Whatman 3MM paper and one piece of transfer membrane (PVDF or nitrocellulose) were cut to the exact size of the SDS-polyacrylamide gel by wearing gloves. The membrane was left in methanol for a few seconds, washed with deionized water and soaked into the transfer buffer for 15 minutes along with Whatman 3MM papers.

### **Preparing of transfer sandwich**

2 wet pieces of Whatman 3MM paper were placed onto the anode plate of the transfer apparatus (Bio-Rad, trans-blot) onto which, the membrane was layered. Then, the gel was transferred on this layer of papers and protein markers were punched by using a needle to replicate them on the membrane. Meanwhile, the corner of the membrane was cut to fix its orientation and the transfer sandwich was completed by putting the other 2 wet pieces of Whatmann 3MM paper. The transfer apparatus was assembled by placing the upper plate (cathode) on the top of transfer sandwich..

The transfer system was connected to the power supply and the transfer was done at constant current of  $3.5 \text{ mA/cm}^2$  of the gel for a period of 45 minutes. Electrical current was turned off and the membrane was removed from the apparatus.

### **Transfer Buffer**

Glycine	2.9 g
Trisma –Base	5.8 g
SDS	0.37 g
Methanol	200 ml
Adjust volume to 1lt with ddH2O	

## **Immunological detection of immobilized proteins (Western Blotting)**

After the transfer process was completed, the membrane was immersed in the blocking solution for one hour to prevent non-specific binding. After washing, supernatants of 6D5 and 9C11 were added and the membrane was incubated with these primary antibodies at room temperature for one hour or at 4° C O/N on a rotating platform. Then the antibodies were removed by three washes of TBS-T, one for 15 minutes and two for 5 minutes. Following the washes, the membrane was incubated with 5000 times diluted secondary antibody (HRP-conjugated rabbit anti-mouse Ig-DAKO) for 1 hour at room temperature. After the final washing step, the membrane was treated with chemiluminescent substrate to visualize transferred proteins.

### **Blocking solution**

5% milk powder in 0.1% Tween-TBS solution.

(Secondary antibody was diluted in blocking solution containing 3% milk powder.)

### **Detection of proteins immobilized on the membrane**

Detection of the protein was done with ECL Plus Western Blotting Kit (Amersham Life Science; Catalog no: RPN 2106). Membrane was taken away from the TBS-T and touching the edge of the membrane to Whatmann 3 MM paper drained excess buffer. ECL Plus, which was prepared according to the manufacturer instruction, was dropped onto the membrane and after 5 minutes films were developed in the dark room by using Automated Developer Machine (Amersham Hyper processor).

### **Equal loading**

Both anti-Calnexin (AF-18) and cytokeratin-18 monoclonal antibodies were used for this purpose. Developed membrane was incubated with blocking solution

and blot processing with either of these antibodies was accomplished as mentioned above (Detection of proteins immobilized on the membrane).

## **2.9.Immunoprecipitation (IP) with 9C11 and 6D5**

Huh-7 cells grown to 70-80% confluency were scraped with ice-cold PBS and stored at  $-80^{\circ}\text{C}$  for protein extraction or immediately lysed in lysis buffer. (150mM Na Cl, 1% NP-40, 50mM Tris pH8, protease inhibitor cocktail-Roche). Meanwhile, the Protein G Gel Slurry (East Coast Biology / R801- H2261) was washed with lysis buffer three times, each for 15 minutes. To avoid non-specific antibody binding, extracted proteins and Protein G beads were co-incubated in microcentrifuge tubes, for 2 hours at room temperature or overnight at  $4^{\circ}\text{C}$  (preclearance). After preclearance, tubes were centrifuged at 2500 rpm for 2 minutes and the supernatants were transferred into fresh tubes. 100  $\mu\text{l}$ . of primary antibody was added and tubes were incubated for 2 hours at room temperature by rotating them constantly. Then, Protein G was added to obtain the triple complex (Antibody+Antigen+Protein G) and tubes were incubated O/N at  $4^{\circ}\text{C}$ . The next day, tubes were centrifuged at 2500 rpm for 2 minutes and supernatants were discarded. Pellets were washed three times with lysis buffer without NP-40 and resuspended in 2X loading buffer. Immunoprecipitated proteins were run in 10% SDS-PAGE and protein transfer and detection were accomplished as described above.

## **2.10.Induction of apoptosis by UV-C**

HUH-7 cells were treated with UV-C to induce apoptosis ( $125\text{mJ}/\text{cm}^2$ ). For this purpose, culture medium was aspirated; cells were washed twice with PBS and exposed to UV irradiation in Petri dishes by using Stratagene UV-Linker Apparatus. Before placing cell culture dishes into the apparatus, washing medium was aspirated and lids of dishes were displaced. Then, fresh medium was added and culture plates were transferred into the  $\text{CO}_2$  incubator. Apoptotic cells were observed under inverted light microscope (Zeiss)

### **2.11.Induction of apoptosis by activation of death-receptor mediated apoptosis**

Jurkat cells derived from a human T-cell leukemia were cultured to subconfluency in RPMI medium up to  $10^6$  cells / ml. Anti-Fas antibody (Upstate Biotechnology-clone CH11) was added to culture flasks at a concentration of 25-50 ng/ml. Cells were collected after 16 hours and pelleted for protein extraction.

### **2.12.Induction of apoptosis by serum starvation**

Hepatocellular carcinoma cells were grown under serum free conditions for three days in order to induce apoptosis. By the end of this period, as the cells started to show morphological characteristics of apoptosis, cells were scraped as previously described and cell pellets were stored at  $-80^{\circ}\text{C}$  for protein extraction.

### **2.13.Induction of apoptosis by oxidative stress**

It was performed in two ways.

- i) Huh-7 cells were incubated in a culture medium containing 0.1% FCS for 72 hrs, and then treated with freshly prepared  $100\ \mu\text{M}$   $\text{H}_2\text{O}_2$ . Cells were collected after minimum 4 hrs (Sayan et al ., 2001).
- ii) Cells were directly treated with  $500\mu\text{M}$   $\text{H}_2\text{O}_2$  .

### **Annexin V assay**

Cells were grown on sterile cover slips treated with Annexin -V-Fluos (Roche Annexin-V-FLUOS staining Kit) for 10 minutes as recommended by manufacturer. Then, cells were observed under fluorescence microscope (Zeiss).



## **2.14.Kinetic assays**

*After UV-induction*, Huh-7 cells were harvested at different periods. At 0; 2; 4; 8; 16 and 24. hour, cell pellets were collected and western blotting and staining experiments were performed.

*After Serum starvation*, cell pellets were taken at 0; 1; 2; 3; 4; 5<sup>th</sup> day and western blotting and staining experiments were performed.

*After 500  $\mu$ M  $H_2O_2$  treatment*, cell pellets were collected at 0; 1; 2; 4; 8; 16; 24<sup>th</sup> hours and western blotting and staining experiments were performed.

*After 100 $\mu$ M  $H_2O_2$  treatment*, pellets were taken at 0; 2; 4; 8; 16; 24<sup>th</sup> hours and then western blotting and staining experiments were performed.


### **3. RESULTS**

Results are explained in the following order:

- \*Production of monoclonal antibodies.
- \*Comparison of Hybridoma clones.
- \*Biochemical characterization of the antigens recognized by 6D5 and 9C11.
  - Western Blotting with 9C11 and 6D5
  - Immunoprecipitation with 9C11 and 6D5.
- \*Expression of 9C11 and 6D5 in apoptotic cells.
- \*Immunofluorescence with 9C11 and 6D5.
- \*Immunoperoxidase with 9C11 and 6D5.


#### **3.1. Production of monoclonal antibodies.**

Balb/C mice were immunized with apoptotic Huh7 cells. Animals were sacrificed and splenic cells were fused with SP2/0 parental myeloma cells. Initially antibody-secreting cells were screened by Cell-ELISA, western blot and immunoprecipitation experiments, and 2 clones, namely 6D5 and 9C11 out of 4 were selected for further characterization studies (Figure 5 and 6). We also demonstrated that 6D5 and 9C11 antibodies recognize different proteins.



**Figure 5. Antibody presence in the supernatants of four hybridomas** were shown, as evidenced by immunoprecipitating supernatants directly with protein G beads and subjecting immunoprecipitates to SDS-PAGE and western blot. 50 kd bands correspond to the heavy chain of antibodies.

### 3.2. Comparison assay for 11G8, 6D5, 6E10 and 9C11



**Figure 6. Immunoprecipitated HUH7 cell lysates** with 9C11, 6D5, 6E10 and 11G8 antibodies and immunoprecipitates were loaded to SDS-PAGE as three

identical sets, except the 11G8 one. After their transfer onto PVDF membrane, each set was probed with 6E10, 6D5, 9C11 and 11G8, respectively (6a). Then, membranes of 9C11 and 6E10 were probed with 11G8 (6b). 6E10, 6D5 and 11G8 antibodies (6a-i; 6a-ii; 6b-iii and 6b-i respectively) were shown to recognize the same antigen, except 9C11, which recognized a different one. Upper bands correspond to proteins recognized by our antibodies (approximately 75 kD), and lower bands indicate the heavy chain of immunoglobulins.

### 3.3. Biochemical characterization

#### Western Blotting with 9C11 and 6D5 monoclonal antibodies

We also investigated the differential expression of proteins recognized by our antibodies, in the context of apoptosis. Total cell lysates from apoptotic and non-apoptotic Huh7 and Jurkat cells were prepared and loaded to 10% SDS-PAGE. After their transfer to PVDF membranes, proteins were probed with 6D5 and 9C11 antibodies. Negative controls, which were not treated with primary antibodies, were also included (not shown). As shown in figure 7., 9C11 antibody recognized both apoptotic and non-apoptotic Huh7 and Jurkat cells (Figure 7. lanes 1, 2, 3 and 4). However, 6D5 antibody failed to react with any protein of Jurkat cells (Figure 7. lanes 5, 6) while recognizing apoptotic and non-apoptotic HUH7 cell lysate (lane 7 and 8 of the same figure). These results clearly demonstrate that 6D5 antibody has a more restricted tissue recognition pattern.




**Figure 7. Western Blotting with 9C11 and 6D5 monoclonal antibodies**

Lane 1: Jurkat; Lane 2: Jurkat+Anti-Fas Antibody; Lane 3: Huh7; Lane 4: Apoptotic Huh7 (Lane 5-6-7-8: same order).


Huh7 cells were exposed to UV-C ( $20 \text{ J/m}^2$ ) in order to induce apoptosis. Jurkat cells were treated with anti-Fas antibody (50 ng /ml) for apoptosis induction. Non-apoptotic and apoptotic cell proteins from both cell lines were probed with 9C11 (lanes 1, 2, 3 and 4) and 6D5 (Lanes 5, 6, 7, 8) in western blotting assay. There was no differential protein expression between non-apoptotic and apoptotic cells.

We also performed western blot experiments to show the binding strength of our antibodies to their cognate ligands. To do this, total cell lysates of HUH7 cells were loaded on SDS-PAGE at different concentrations varying from  $1 \mu\text{g}$ . to  $20 \mu\text{g}$ . Even the lowest concentration of proteins reacted with 9C11 (figure 8a) and 6D5 (figure 9a). Apoptotic cells show less band intensity than non-apoptotic cells (Lanes 2, 4, 6, 8 in figure 8a and 9a).



**Figure 8. Different protein concentrations with 9C11.** Lysates that had been obtained from both apoptotic and non-apoptotic Huh7 cells were run in 10% SDS-PAGE at concentrations indicated below and transferred to PVDF membrane.

Lane 1: non-apoptotic -1 $\mu$ g, Lane 2: apoptotic -1  $\mu$ g, Lane 3: non-apoptotic-5  $\mu$ g, Lane 4: Apoptotic -5  $\mu$ g, Lane 5: non-apoptotic -10  $\mu$ g, Lane 6: Apoptotic-10  $\mu$ g, Lane 7: non-apoptotic - 20  $\mu$ g, Lane 8: Apoptotic-20  $\mu$ g, Lane 9: negative control (not probed with 9C11). Membrane was probed with 9C11 to show the antibody strength (a) and with anti-CK-18 mAb to check the protein amounts that were loaded (b).




**Figure 9. Different protein concentrations with 6D5.** Lysates that had been obtained from both apoptotic and non-apoptotic Huh7 cells were run in 10% SDS-PAGE at concentrations indicated below and transferred to PVDF membrane.

Lane 1: non-apoptotic -1 $\mu$ g, Lane 2: apoptotic -1  $\mu$ g, Lane 3: non-apoptotic-5  $\mu$ g, Lane 4: Apoptotic -5  $\mu$ g, Lane 5: non-apoptotic -10  $\mu$ g, Lane 6: Apoptotic-10  $\mu$ g, Lane 7: non-apoptotic - 20  $\mu$ g, Lane 8: Apoptotic-20  $\mu$ g, Lane 9: negative control (not probed with 6D5). Membrane was probed with 6D5 to show the antibody strength (a) and with anti-CK-18 mAb to check the protein amounts that were loaded (b).

### 3.4 Kinetic Assays in different apoptosis induction methods

#### 3.4.1 UV induction


HUH7 cells were exposed to UV-C irradiation to induce apoptosis and cell lysates were collected at different time course. As shown in figure 10, there was a significant signal reduction in early apoptotic stage (2, 4 and 8th hours.), but the protein expression was recovered in 16th and 24th hours. The differential expression was more obvious in equal loading membrane (figure 10b lower bands), since the bands in the membrane probed with 9C11 were at saturation (figure 10a).



**Figure 10. Kinetic assay in UV-induced apoptosis.**

Huh7 cells were treated with UV-C and cells were harvested at different periods. Lane 1: No UV induction, Lane 2-6: 2, 4, 8, 16, 24 hrs respectively after UV induction. Total lysates of these cells were run in SDS-PAGE and proteins were

probed with 9C11 after their transfer onto PVDF membrane (a). Equal loading was performed with AF-18, anti-calnexin monoclonal antibody (b). The same pattern was also observed in the experiment performed with 6D5 but, several bands appeared in the membrane probed with this antibody (figure 11a). These results lead us to speculate that the protein recognized by 6D5 antibody might have different isoforms or distinct proteins sharing a common epitope were visualized in our western blots.




**Figure 11. Kinetic assay in UV-induced apoptosis.**

Huh7 cells were treated with UV-C and cells were harvested at different periods. Lane 1: No UV induction, Lane 2-6: 2, 4, 8, 16, 24 hrs, respectively after UV induction. Total lysates of these cells were run in SDS-PAGE and proteins were probed with 6D5 after their transfer onto PVDF membrane (a). Equal loading was performed with AF-18, anti-calnexin monoclonal antibody (b, upper bands).



### Annexin V Assay

One of the most common techniques used is the detection of phosphatidylserine in the outer leaflet of the plasma membrane of apoptotic cells, using labelled annexin V. Therefore, we confirmed the occurrence of apoptosis after treatment of Huh7 cells with UV-C irradiation by using Annexin V assay (figure 12).




**Figure 12. Annexin V Assay.** Apoptosis was induced by UV-C irradiation (  $20 \text{ J/m}^2$  ) and cells were subjected to Annexin V assay at 4<sup>th</sup> and 24<sup>th</sup> hour after treatment (A and C, respectively). Untreated cells were used as negative controls for indicated times (B and D, respectively).

### 3.4.2. Starvation

Huh7 cells were grown in serum free conditions to induce apoptosis and cell lysates were collected at different time course. Control cells grown in DMEM-10 and DMEM-0 supported with 100 nM selenium were also included in the experiment, since such growth conditions do not allow apoptosis to occur. The follow-up of apoptosis development was performed by morphological analysis of starved cells under inverted microscope (data not shown). Total lysates of these cells were run in SDS-PAGE and proteins were probed with 9C11 (figure 13) and 6D5 (figure 14a)

after their transfer onto PVDF membrane. Equal loading was performed with AF-18, anti-calnexin monoclonal antibody (figure 13b and figure 14b) .

Under starvation condition, HUH7 cells have been reported to undergo apoptosis starting from day 3, and increase in the following days (Sayan et al, 2002.). In our starvation assay, we observed, as in UV-induced apoptosis experiment, that proteins recognized by 9C11 and 6D5 antibodies were down-regulated in the early phases of apoptosis (day 3; figure 13-lane 5 and figure 14a-lane 5). However, the band intensity of proteins were recovered in day 4 and 5 (figure 13 and 14a, lanes 6 and 7). This result was also consistent with our previous observation in UV-induced apoptosis assay, in which the same recovery was encountered in the late phase of apoptosis (figures 6a, 6b, 7a and 7b; lanes 5 and 6).




**Figure 13. Kinetic assay in starvation with 9C11**


Cells were grown in serum free conditions to induce apoptosis. Total lysates of these cells were run in SDS-PAGE and transferred onto PVDF membrane. Proteins were probed 9C11 (lower bands) and AF-18 (upper bands), anti-calnexin monoclonal antibodies.

Lane 1: Control 1 (DMEM-10), Lane 2: control 2 (DMEM-0 containing 100 nM selenium), Lane 3-7: day 1, day 2, day 3, day 4 and day 5, respectively after starvation.

**a.**



**b.**




**Figure 14. Kinetic assay in starvation with 6D5**

Cells were grown in serum free conditions to induce apoptosis. Total lysates of these cells were run in SDS-PAGE and transferred onto PVDF membrane. Proteins were probed with 6D5 (a) and AF-18 (b), anti-calnexin monoclonal antibodies.

Lane 1: Control 1 (DMEM-10), Lane 2: control 2 (DMEM-0 containing 100 nM selenium), Lane 3-7: day 1, day 2, day 3, day 4 and day 5, respectively after starvation.


### 3.4.3. H<sub>2</sub>O<sub>2</sub> treatment

The fact that cells undergo apoptosis with reactive oxygen species (ROS) and direct treatment of H<sub>2</sub>O<sub>2</sub> has been well established. In this context, we treated Huh7 cells with 500  $\mu$ M H<sub>2</sub>O<sub>2</sub> and collected cells at different times after treatment. However, we did not observe any morphological changes indicating apoptosis induction under this experimental condition (data not shown). Lysates were prepared and proteins were run in 10% SDS-PAGE. After transfer of proteins, PVDF membranes were probed with 9C11 (figure 15) and 6D5 (figure 16a). Unlike UV-induced and starvation-induced apoptosis, H<sub>2</sub>O<sub>2</sub> treatment caused a gradual decrease in the band intensity of proteins recognized by 6D5 (figure 16a), without any recovery event in the late phases of apoptosis. On the other hand, we could not make such a conclusion in the case of 9C11 antibody, because of equal loading problem (Figure 15), yet decreased expression of proteins in the late phases of treatment was observed (Figure 15 lanes 6 and 7).



**Figure 15. Kinetic assay in oxidative stress with 9C11.**

Lane 1: Control (no H<sub>2</sub>O<sub>2</sub> treatment), Lane 2-7: 1 hour, 2 hours, 4 hours, 8 hours, 16 hours, and 24 hours, respectively after H<sub>2</sub>O<sub>2</sub> treatment. Lane 8: negative control (lysate from untreated cell loaded but not probed with primary antibody). Membrane probed at a time with 9C11 (lower bands), and AF-18 (upper bands).




**Figure 16. Kinetic assay in oxidative stress with 6D5**

Lane 1: Control (no  $\text{H}_2\text{O}_2$  treatment), Lane 2-7: 1 hour, 2 hours, 4 hours, 8 hours, 16 hours, and 24 hours, respectively after  $\text{H}_2\text{O}_2$  treatment. Membrane was probed with 6D5 (a) and equal loading was performed with CK18 mAb (b).


#### **3.4.4. Starvation and $\text{H}_2\text{O}_2$ treatment**

A more intensive oxidative stress condition was also established. To do this, Huh7 cells were grown in 0.1% FCS for 72 hours and then treated with 100  $\mu\text{M}$   $\text{H}_2\text{O}_2$ . Apoptotic cells were observed under light microscope even before the addition of  $\text{H}_2\text{O}_2$  into the culture (data not shown). Cells were collected at different times and lysates were prepared. Proteins were run in 10% SDS-PAGE transferred to PVDF membrane. This time, starvation alone caused a decrease in the expression of proteins recognized by both 9C11 and 6D5 (lane 2 of figure 17a and 18a,

respectively) and expression was recovered in the very late phase of oxidative stress conditions (Lane 7 of figure 17a and 18a, respectively). While evaluating these results, one should consider that proteins were overloaded in lanes 3 and 4 of figures 17a and 18a.



**Figure 17. Kinetic assay in starvation and oxidative stress with 9C11.** Lane 1: Control (DMEM-10), Lane 2: (DMEM-0.1 without  $H_2O_2$  treatment), Lane 3-7: 2, 4, 8, 16, 24 hours after treatment. Membrane was probed with 9C11 (a) and equal loading was performed with AF-18 (b).



**Figure 18. Kinetic assay in starvation and oxidative stress with 6D5.** Lane 1: Control (DMEM-10), Lane 2: (DMEM-0.1, without  $H_2O_2$  treatment), Lane 3-7: 2, 4,


8, 16, 24 hours after treatment. Membrane was probed with 9C11 (a) and equal loading was performed with with CK-18 (b).

### **3.5 Immunofluorescence and Immunoperoxidase with 9C11 and 6D5**

We continued our experiments with immunofluorescence and immunoperoxidase staining assays to verify western blot data. These studies allowed us to detect cellular localization of proteins recognized by 9C11 and 6D5, as well as the intensities of antibody reactivities depending on different apoptosis induction assays. Cells were grown on the sterile cover slips and fixed with ice-cold methanol. After their treatment with either antibody, fixed cells were treated with FITC or peroxidase conjugated secondary antibody and counterstaining was accomplished by Hoechst 33258 or hematoxyline for immunofluorescence and immunoperoxidase, respectively.


#### **3.5.1 Kinetic assay in UV-induced apoptosis**

Apoptosis was induced as previously described (3.4.1.). Cover slips were collected at times indicated (Figure 19, 20) and cells were subjected to immunofluorescence assay. Concordant with our western blot experiment (Figure 10, 11), a decrease in the signal intensity during early phase of apoptosis was observed (C, E), and the expression of protein was recovered at the late phase (I, K). Non-apoptotic cells were included as positive control (A) and displayed strong staining pattern.



**Figure 19. Immunofluorescence with 9C11 in UV induction.** A-C-E-G-I-K, nonapoptotic; 2, 4, 8, 16 and 24 hrs after treatment, respectively; B-D-F-H-J-L, counterstaining with Hoechst 33258. Primary antibody: 9C11. Cells not treated with primary antibody were used as negative controls (not shown).






**Figure 20. Immunofluorescence with 6D5 in UV induction.** A-C-E-G-I-K: nonapoptotic, 2, 4, 8, 16 and 24 hrs after treatment, respectively; B-D-F-H-J-L: counterstaining with Hoechst 33258. Primary antibody: 6D5. Cells not treated with primary antibody were used as negative controls (not shown)


### 3.5.2. Kinetic assay in starvation

Immunofluorescence was performed after cells were grown under serum-free conditions. Signal decrease at day 3 and recovery of the signal intensity at days 4 and

5 of starvation, justified the western blot data (Figure 21 I, K, M; Figure 22 I, K, M). Unstarved cells were used as positive controls (Figure 21 A; Figure 22 A). It has been shown that serum-free medium containing 100 nM selenium protect cells to undergo apoptosis in starvation conditions, however we observed a slight decrease in signal intensity in cells supplied with selenium (Figure 21 C; Figure 22 C).




**Figure 21. Immunofluorescence with 9C11 in starvation. A-C-E-G-I-K-M:** DMEM10, DMEM0+Selenium, 1, 2, 3, 4 and 5 days after treatment, respectively; **B-D-F-H-J-L-N:** counterstaining with Hoechst 33258, respectively. Primary antibody: 9C11. Cells not treated with primary antibody were used as negative controls (not shown). White arrow indicates apoptotic cells.



**Figure 22. Immunofluorescence with 6D5 in starvation. A-C-E-G-I-K-M:** DMEM10, DMEM0+Selenium, 1, 2, 3, 4 and 5 days after treatment, respectively; **B-D-F-H-J-L-N:** counterstaining with Hoechst 33258, respectively. Primary antibody: 6D5. Cells not treated with primary antibody were used as negative controls (not shown). White arrow indicates apoptotic cells.


### 3.5.3 Kinetic assay in oxidative stress.

As previously explained in (3.4.3), oxidative stress condition was generated by treating cells with 500  $\mu\text{M}$   $\text{H}_2\text{O}_2$  and cells were collected at indicated times. After their incubation with 9C11 and 6D5 antibodies, immunoperoxidase staining was performed (Figure 23; Figure 24). Unlike UV induction and starvation conditions, a gradual decrease in the staining intensity was observed with either antibody (Figure 23. A, B, C, D, E, F, G; Figure 24. A, B, C, D, E, F, G).



**Figure 23. Immunoperoxidase assay in oxidative stress with 9C11.** Cells were treated with 500  $\mu\text{M}$   $\text{H}_2\text{O}_2$ . **A-B-C-D-E-F-G:** Cells grown in DMEM-10 only; and

cells collected after 1, 2, 4, 8, 16 and 24 hrs of treatment, respectively. Counterstaining was performed with hematoxyline. Cells not treated with primary antibody were used as negative control **H**. Primary antibody was 9C11.




**Figure 24. Immunoperoxidase assay in oxidative stress with 6D5.** Cells were treated with 500  $\mu\text{M}$   $\text{H}_2\text{O}_2$ . **A-B-C-D-E-F-G:** Cells grown in DMEM-10 only; and cells collected after 1, 2, 4, 8, 16 and 24 hrs of treatment, respectively. Counterstaining was performed with hematoxyline. Primary antibody was 6D5.




### 3.5.4. Kinetic assay in starvation and oxidative stress.

We established a more rigorous oxidative stress condition as described in (3.4.4) and performed immunoperoxidase staining. When treated with 9C11 monoclonal antibody, protein down-regulation was observed; verifying previously accomplished western blot experiment (Figure 25 B, C). Starting from 8 hrs after treatment of starved cells with 100  $\mu$ M H<sub>2</sub>O<sub>2</sub>, protein expression was recovered (Figure 25 D, E, F). Untreated cells grown in DMEM-0.1 (starvation condition) were used as positive controls (Figure 25 A; Figure 26A). However in our assay with 6D5 antibody, we could not reproduce our western blot data, yet a decrease in staining intensity was evident at 16 hrs after treatment (Figure 26E) Without any recovery thereafter.



**Figure 25. Immunoperoxidase assay in starvation and oxidative stress with 9C11.** Huh7 cells were grown in DMEM-0.1 for 72 hours and then treated with 100  $\mu$ M H<sub>2</sub>O<sub>2</sub>. **A-B-C-D-E-G-F:** Cells grown in DMEM-0.1 only; and cells collected after 2, 4, 8, 16 and 24 hrs of treatment, respectively. 9C11 was used as primary antibody. Cells not treated with primary antibody were used as negative controls (not shown).



**Figure 26. Immunoperoxidase assay in starvation and oxidative stress with 6D5.**

Cells were grown in DMEM-0.1 for 72 hours and then treated with 100  $\mu$ M  $H_2O_2$ .

**A-B-C-D-E-G-F:** Cells grown in DMEM-0.1 only; and cells collected after 2, 4, 8, 16 and 24 hrs of treatment, respectively. 6D5 was used as primary antibody. Cells not treated with primary antibody were used as negative controls (not shown).



#### **4. DISCUSSION**

Since their discovery in 1975, thousands of monoclonal antibodies have been used in several fields of biology such as basic research, and diagnosis, monitoring and treatment of many diseases. Several hundreds of proteins have been characterized in research laboratories by using these powerful tools. Monoclonal Abs have become key components in a vast array of clinical laboratory diagnostic tests. In diagnostic approaches, their wide application in detecting and identifying cell markers and pathogenic agents has largely arisen. In recent years, about ten monoclonal antibodies have been approved by US Food and Drug Administration (FDA) and launched on the market to be used for the treatment of cancer and degenerative diseases.

One recent report emerged from our department and describing a monoclonal antibody namely NAPO (Sayan et al., 2001), clearly identified the disappearance of a nuclear protein in apoptotic cells and encouraged us to develop new monoclonal antibodies that may recognize proteins differentially expressed in apoptosis. To do this, mice were immunized with apoptotic Huh7 hepatocellular carcinoma cells and four clones strongly reacting with these cells were obtained. The reason for choosing this cell line was that detachment of apoptotic cells from the surface of culture plates is a major problem in experimental research, and that Huh7 cells remain tightly adhered even when strong apoptosis inducing stimuli were applied.

Among the two monoclonal antibodies out of four, which were studied in these MSc thesis work in the context of apoptosis, 9C11 recognizes a protein of

approximately 75 kDa in Huh-7 cells, whereas protein reacting with 6D5 has distinct isomers most probably due to alternative splicing or truncation events. In our experiments (Figure 2), it was shown that 11G8, 6D5 and 6E10 recognize the same protein, but whether they bind to same epitope or not is not clear since we did not accomplished fine epitope mapping of these antibodies. However, 9C11 and 6D5 differ from each other, being reacted with distinct ligands. Amino acid sequencing of proteins recognized by 9C11 and 6D5 antibodies could not be done so far, since such procedure requires a large amount of protein to be transferred onto PVDF membrane; yet we performed some preliminary experiments for optimizing the experimental conditions.

Immunoprecipitation experiments showed that 9C11 recognizes its antigen both in apoptotic and non-apoptotic Huh7 and Jurkat cells, whilst the reaction of 6D5 was restricted to Huh-7 cells in both experimental conditions (Figure 3). This result confirmed clearly our observation that 6D5 and 9C11 differ in their target ligands and that 6D5 has more restricted tissue specificity. Since we detected strong band intensity during all western blot experiments, we concluded that antigens recognized by both antibodies are expressed abundantly in Huh-7 cells. Moreover, the immunoreactivity of 9C11 and 6D5 with their ligands was strong enough to distinguish their antigens even at low concentrations of total protein (Figure 4 and 5). Another explanation of this intense reactivity may result from the high affinity of our antibodies to their ligands.

Apoptosis, or programmed cell death, is a physiological death essential for normal development and maintenance of homeostasis (Yonehara, 2002). Biochemical changes in chromatin and DNA degradation provide useful and often quantifiable means of detecting apoptosis. Besides DNA degradation, exteriorization of phosphatidylserine on plasma membrane occurs during apoptosis. This change allows binding of the anticoagulant protein annexin V to phospholipids with a great affinity (Studzinski et al., 1999). This feature serves to detect and discriminate apoptosis from other cell death types. Another detection method is TUNEL assay (TdT-mediated conjugated dUTP nick end-labeling). DNA fragmentation is

considered to be a key event to detect apoptosis (DNA fragmentation assay); however, this method is not used to evaluate apoptosis in relation to histological localization and this obstacle may be overwhelmed by TUNEL assay.

Apoptosis can be activated by a number of extrinsic or intrinsic signals. In various apoptosis induction conditions performed during this study, protein ligands of 9C11 and 6D5 showed similar pattern in terms of the regulation of expression. Such observation derived from both western blot and immunostaining experiments in which differential expression of target proteins was detected in early and late phases of apoptosis. When apoptosis was induced with UV-C, down regulation of 9C11 protein occurred starting from the 2<sup>nd</sup> hour up to 8<sup>th</sup> hour, and its expression was recovered at 16<sup>th</sup> after treatment lasting up to 24<sup>th</sup> hour (Figure 10). In UV-induction assays performed with 6D5 antibody, the same protein expression pattern was observed, as being a down-regulation in early phase and up-regulation in late phase of apoptosis (Figure 11).

The same protein expression pattern was also observed when we induced apoptosis by culturing cells in serum-free medium (Figure 13, 14) and serum starvation followed by the treatment of cells with 100  $\mu$ M of H<sub>2</sub>O<sub>2</sub> (Figure 17, 18). One explanation for all of these observations might be the loss of apoptotic cells in the late phases of apoptosis and harvesting only cells bypassing cell death. In that case, the latter cells would be compared with non-apoptotic control cells and this would mislead us to the conclusion that protein expression was recovered in final stages of apoptosis in our experimental conditions. However this was not the case, at least in UV-induced apoptosis experiments, since we detected up-regulation of late apoptotic proteins when compared with untreated controls. Moreover, when we examined the morphology of cells under microscope and performed Annexin V assay with these cells, we observed that the ratio of apoptotic cells increased significantly at times most distant from the start point of experiments (Figure 12). These two observations constitute another evidence confirming that we collected apoptotic cells as expected and compared them with non-apoptotic controls. However, when oxidative stress condition was established by simply adding 500  $\mu$ M of H<sub>2</sub>O<sub>2</sub>, a

gradual decrease in the signal intensity of proteins was detected in experiments accomplished with both antibodies (Figure 15, 16) without any recovery of protein expression.

Although the transcriptional regulation of apoptosis has been extensively studied (Fritz et al., 1999), data explaining its translational regulation were missing. Recent studies clearly indicated that inhibition of protein synthesis in apoptotic processes is due to endoplasmic reticulum (ER) stresses resulting in unfolded protein response (UPR). UPR consists of the activation of transcription allowing the expression of components that protect cells from stress (Kaufman et al., 2002). Meanwhile, a transient translation attenuation of protein synthesis is also observed. Studies reported that this inhibition is coupled to the phosphorylation of eukaryotic translation initiation factor 2 (eIF2 $\alpha$ ), reducing the frequency of AUG codon recognition (Kaufman et al., 2002). The role of activated caspase in translation inhibition has been also questioned in another study (Marissen et al., 2000). These authors demonstrated that eIF2 $\alpha$  and another translation initiation factor (eIF4GI) were targets of the caspase 3 and that caspase inhibitor might prevent protein synthesis inhibition. The same group also showed that translation might continue up to 24 hours after treatment of cells with DNA damaging agents. This issue is especially important for us, since we detected a translational activity in the late phase of apoptosis. Moreover, one should also note that generalized translation attenuation upon various stress stimuli inhibits anti-apoptotic proteins, whereas UPR-dependent transcriptional activity induces the expression of pro-apoptotic ones. This dual regulatory mechanism assures the progression of apoptosis process in cells through either extrinsic or intrinsic apoptotic pathways.

However, despite the presence of accumulating data, the mechanism underlying protein synthesis inhibition in apoptosis has been partly elucidated and a multifactorial causality has been suggested.

In our experimental approaches, oxidative stress induction with 500  $\mu$ M of H<sub>2</sub>O<sub>2</sub> failed to display a translational activity in the late phase of apoptosis, but rather, a gradual decrease in the expression of proteins was detected. This could be

due to the insufficiency of that stimulus for cells to induce apoptosis, since we could not observe morphologically any apoptotic phenotype. Another explanation might be the relatively late action of the stimulatory agent on cells for apoptosis induction, since we ended the experiment at 24<sup>th</sup> hour after treatment.

In conclusion, we proceeded in the characterization of two monoclonal antibodies in the context of apoptosis and found in all designed experiments a protein down-regulation in the early phases of cell death process. In contrast, a translational activity and to some extent an up-regulation of proteins recognized by our antibodies were observed in the late phases, except the case of oxidative stress induction with 500  $\mu$ M of H<sub>2</sub>O<sub>2</sub>, where a gradual protein down-regulation persisted throughout the assay. Furthermore, we sought the validity of our western blot data by performing immunofluorescence and immunoperoxidase staining experiments, in which cells were subjected to the same assay conditions as western blot studies. These latter assays also revealed that both antibodies recognize proteins at the perinuclear zone of Huh-7 cells, leading us to speculate ER localization.

These works should continue with the complete characterization of these two antibodies. The most direct way to accomplish this task is to identify the amino acid sequence of proteins recognized by 9C11 and 6D5. This could be done either by N-terminal amino acid sequencing (Edman Degradation) or by subjecting purified ligand fragments to Liquid Chromatography-Mass Spectrometry (LC-MS), which would follow a protein database search through identified amino acid sequence of peptide fragments. Then, the differential expression of proteins might be evaluated in apoptotic processes and the value of our antibodies as novel apoptotic markers might be assessed. Once characterized, another valuable approach to study apoptosis would be the investigation of the transcriptional regulation of these ligands.

Finally, agonistic and antagonistic effects of these antibodies to induce or to prevent apoptosis, respectively would be of great importance, since many such antibodies were introduced into clinical trials for the treatment of cancers and degenerative diseases.

## REFERENCES

Abbas AK and Lichtman AH Cellular and Molecular Immunology. *Elsevier Science*. 2003, Saunders Company, fifth edition, 45.

Adams J and Cory S: The Bcl-2 protein family: arbiters of cell survival. *Science* 1998, Aug 28; 281(5381): 1322-6.

Avi Ashkenazi.Targeting Death and Decoy Receptors of the tumour-necrosis factor superfamily. *Nat Rev Cancer* 2002, 2(6): 420-30

Breedveld FC: Therapeutic monoclonal antibodies. *Lancet* 2000, 355: 735-40

Berna S. Sayan, Gulayse Ince, A. Emre Sayan, and Mehmet Ozturk: NAPO as a Novel Marker for Apoptosis.*The Journal of Cell Biology* 2001, 155(5): 719-724.

Chen CJ, Yu MW, Liaw YF.Epidemiological characteristics and risk factors of hepatocellular carcinoma. *J Gastroenterol Hepatol* 1997, 12(9-10): S294-308.

Degtrev A, Boyce M, Yuan: A decade of caspases. *Oncogene*, 2003 24; 22(53):8543-67.

Deveraux QL, Reed JC: IAP family proteins-suppressors of apoptosis *Genes Dev* 1999, 13:239-252

Dominguez-Malagon H, Gaytan-Graham S: Hepatocellular carcinoma: an update. *Ultrastruct Pathol* 2001, 25(6): 497-516.

Durr R, Caselmann WH: Carcinogenesis of primary liver malignancies. *Langenbecks Arch Surg* 2000, 385 (3): 154-61.

DW. Nicholson: Caspase structure, proteolytic substrates, and function during apoptotic cell death. *Cell death and differentiation* 1999, 6: 1028-1042.

Esma Yolcu, Berna Sayan, Tamer Yağcı, Rengül Çetin Atalay, Thierry Soussi, Nevzat Yurdusev and Mehmet Öztürk: A monoclonal antibody against DNA binding helix of p53 protein. *Oncogene* 2001, 20: 1398-1401.

Fritz, G., and Kaina, B: Ultraviolet Light Inhibits Translation through Activation of the Unfolded Protein Response Kinase PERK in the Lumen of the Endoplasmic Reticulum *Mol. Cell. Biol.* (1999) 19, 1768–1774

Fulda,S.,Meyer,E.,Friesen,C.,Susin,S.A., Kroemer,G., and Debatin,K.M..Cell type spesific involvement of death receptor and *mitochondrial* pathways in drug induced apoptosis.*Oncogene* 2002, 20: 1063-1075.

Gavrieli,Y.,Sherman, Y. And Ben Sasson, S.A: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. *J. Cell. Biol.* 1992, 119, 493.

George P Studzinski: Apoptosis A Practical approach.*Oxford University Press* 1999, 6;157.

Green,D.R: Apoptotic pathways:paper wraps stone blunts scissors.*Cells* 200, 102: 1-4.

Hockenbery DM,Oltvai ZN, Yin XM,Milliman CL,Korsmeyer SK: Bcl-2 functions in an antioxidant pathway to prevent apoptosis.*Cell* 1993, 75:241-251.

Hoffmann, P. M. Jiménez-Díaz, J. Weckesser, W.G. Bessler: Murine bone marrow-derived macrophages constitute feeder cells for human B cell hybridomas.



*J Immuno Methods* 1996, 196: 85-91.

Jaattela M, Wissing D, Kokholm K, Kallunki T, Egeblad M. Hsp70 exerts its anti-apoptotic function downstream of caspase-3-like proteins *EMBO J* 1998, 17: 6124-6134

Jun-Hwan Yoon, Gregory J. Gores Death receptor-mediated apoptosis and the liver. *Journal of Hepatology* 2002, 37: 400-410

Kerr JFR, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer* 1972, 26:239-257

Klaus Schulze-Osthoff, Davide Ferrari: Apoptosis signaling by death receptors. *Eur.J.Biochem* 1998, 254: 439-459

L Stergiou and MO Hengartner. Death and more: DNA damage response pathways in the nematode *C.elegans*. *Cell Death and Differentiation* 2004, 11: 21-28.

Li Ji , Chung-Yang Huang, Rong-Liang Zheng, Kai-Rong Cui and Jian-Feng Li. Hydrogen Peroxide induces apoptosis in human hepatoma cells and alters cell redox status. *Cell Biology International* 2000, 24: 19-23.

Marian Miller, Anastasia Andringa. Insight into UV-induced apoptosis: Ultrastructure, trichrome stain and spectral imaging. *Micron* 33 2002, 157-166

Nelson PN, Reynolds GM, Waldron EE, Ward L, Giannopoulos K, Murray PG: Monoclonal antibodies *J Clin Pathol: Mol Pathol* 2000, 53: 111-7

Nesrin Özören and Wafik S. El-Deiry. Defining Characteristics of Type I and II Apoptotic Cells in response to TRAIL. *Neoplasia* 2002, 4 (6) 551-557.

Rajeev Goel and K. L. Khanduja: Oxidative stress-induced apoptosis – An overview. *Banner* 1998, 75: 1338.

Randal J. Kaufman, Donalyn Scheuner, Martin Schröder, Xiaohua Shen, Kyungho Lee, Chuan Yin Liu & Stacey M. Arnold. The Unfold Protein Response in Nutrient Sensing and Differentiation. *Molecular Cell Biology* 2002, 3: 411-421

Reed J: Bcl-2 family proteins. *Oncogene* 1998, 17:3225-3236

Richard E. Lloyd: Identification of Caspase 3-mediated Cleavage and Functional Alteration of Eukaryotic Initiation Factor 2 in Apoptosis. *J Biol Chem* 2000, 275(13) 9314-9323.

Richter C: Pro-oxidants and mitochondrial Ca<sup>2+</sup>: their relationship to apoptosis and oncogenesis. *FEBS Lett.* 1993, 28; 325(1-2): 104-7.

Shaliaja Kakibhatla and Ben Tseng: Why target apoptosis in Cancer Treatment? *Molecular Cancer Therapeutics* 2003, 2: 573-580.

Shin Yonehara: Death receptor Fas and autoimmune disease: from the original generation to the therapeutic application of agonistic anti-Fas monoclonal antibody. *Cytokine and Growth Factor Reviews* 2002, 13: 393-402.

Sudhir Gupta: Molecular steps of death receptor and mitochondrial pathways of apoptosis. *Life Sciences* 2002, 69: 2957-2964

Wilfred E. Marissen, Yanwen Guo, Adri A. M. Thomas, Robert L. Matts, and Martin Zörnig, Anne-Odile Hueber. Apoptosis regulators and their role in tumorigenesis. *Biochimica et Biophysica Acta* 2001, 1551: F1-F37.

Wyllie AH: Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. *Nature* 1980, 284:555-556